Abnormal lipid metabolism and associated metabolic disorders are important complications of HIV infection. The mechanism(s) underlying these alterations may be related to HIV itself and/or treatment with antiretrovirals. The MDR1 gene product P-gp is an important determinant of the disposition, pharmacokinetics and drug interactions of drugs used in the treatment of HIV, its complications, and related conditions such as drug abuse. The HIV protease inhibitors (PIs) interact with P-gp, but the results from diverse experimental paradigms are often conflicting. It is not established how the PIs affect MDR1 over the range of exposure conditions that occur at the various anatomic sites where MDR1 is active. PIs can acutely inhibit the function of MDR1 but can lead to MDR1 over expression with chronic exposure. The individual PIs differ in their ability to have an impact on MDRI. In addition to shaping the kinetic profile of drug substrates, MDR1 is one of a group of ABC transport proteins involved in lipid homeostasis, including the uptake of cholesterol in the intestine. Another ABC transporter, ABCA1, is also important in cholesterol transport, and defects in this gene can result in familial high-density lipoprotein deficiency and Tangier disease. MDR1 and ABCA1 appear to work together under certain circumstances, and knowing how the PIs affect MDR1 and ABCA1 would provide insight into how the PIs could affect transport of cholesterol and other lipids. Additionally, the MDR1 gene promoter region contains a site for NFkB, a ubiquitous transcription factor with roles in many diverse processes, including atherosclerosis and insulin resistance. Limited data indicate ritonavir affects NFkB activation, but little is known about whether there are differential effects from acute and chronic exposure or across the class of PIs. This proposal will explore the relationship between the PIs and MDR1, as well as two other proteins with relationships to MDR1. Cell culture models will examine transporter mRNA, protein and function over a range of physiologically relevant PI concentrations. The response of NFkB in these same cells will be determined. Additionally, cholesterol uptake in the cell culture model will be examined under the same conditions. The findings will be of importance in understanding lipid disorders related to PIs as well as the kinetics of drugs used to treat HIV and related disorders. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI058784-02
Application #
6954257
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Brobst, Susan W
Project Start
2004-09-30
Project End
2007-08-31
Budget Start
2005-09-01
Budget End
2007-08-31
Support Year
2
Fiscal Year
2005
Total Cost
$245,250
Indirect Cost
Name
Tufts University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
039318308
City
Boston
State
MA
Country
United States
Zip Code
02111
Rhee, Martin S; Hellinger, James A; Sheble-Hall, Sandy et al. (2010) Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir). J Clin Pharmacol 50:392-400
Oleson, L; von Moltke, L L; Greenblatt, D J et al. (2010) Identification of polymorphisms in the 3'-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica 40:146-62
Gan, Lu; von Moltke, Lisa L; Trepanier, Lauren A et al. (2009) Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes. Drug Metab Dispos 37:90-6
Farkas, D; Volak, L P; Harmatz, J S et al. (2009) Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin Pharmacol Ther 85:644-50
He, Xi; Hesse, Leah M; Hazarika, Suwagmani et al. (2009) Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol 68:721-30
Kwara, Awewura; Lartey, Margaret; Sagoe, Kwamena W et al. (2008) Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol 48:1032-40
Greenblatt, David J; von Moltke, Lisa L (2008) Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 48:1350-5
Farkas, Dora; Greenblatt, David J (2008) Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin Drug Metab Toxicol 4:381-93
Knox, Tamsin A; Oleson, Lauren; von Moltke, Lisa L et al. (2008) Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 49:358-68
Perloff, Michael D; von Moltke, Lisa L; Fahey, Jeanne M et al. (2007) Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol 59:947-53

Showing the most recent 10 out of 25 publications